Cioffi George A

Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.

With technologies available when the studies were conducted, daily treatment with memantine over 48 months was not shown to prevent glaucomatous progression in this patient population.

Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial.

A combination of nicotinamide and pyruvate yielded significant short-term improvement in visual function, supporting prior experimental research suggesting a role for these agents in neuroprotection for individuals with glaucoma and confirming the need for long-term…

Association Between Undetected 10-2 Visual Field Damage and Vision-Related Quality of Life in Patients With Glaucoma.

The 10-2 VF model showed a stronger association with NEI VFQ-25 score than the 24-2 VF model.

Detecting glaucoma with only OCT: Implications for the clinic, research, screening, and AI development.

In section 5, the model helps account for the success of an AI deep learning model, which in turn validates our focus on the RNFL p-map.

Structure-Function Agreement Is Better Than Commonly Thought in Eyes With Early Glaucoma.

There is good agreement between structural and functional damage, even in eyes with confirmed early glaucomatous damage, if both 24-2 and 10-2 VFs are obtained, and abnormal locations on the VFs are compared to abnormal regions seen on OCT macular and disc scans.

Oxidative Stress-Related Molecular Biomarker Candidates for Glaucoma.

Findings of this study encourage further validation studies of oxidative stress-related biomarkers in glaucoma.

T-Lymphocyte Subset Distribution and Activity in Patients With Glaucoma.

These findings suggest that the immunity activated in glaucoma may not be counterbalanced by an efficient immune suppression.

Genetic Architecture of Primary Open-Angle Glaucoma in Individuals of African Descent: The African Descent and Glaucoma Evaluation Study III.

A novel association with advanced POAG in the EN04 locus was identified putatively in persons of AD.

New Recommendations for the Treatment of Systemic Hypertension and their Potential Implications for Glaucoma Management.

Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome.

The ocular surface microbiome of patients taking unilateral preserved glaucoma drops is characterized by a highly diverse array of gram-negative bacteria that is significantly different from the predominantly gram-positive microbes detected on healthy control eyes.

Association of Glaucoma-Related, Optical Coherence Tomography-Measured Macular Damage With Vision-Related Quality of Life.

Characteristic patterns of glaucoma-related macular RGC+IPL loss appeared to be more important predictors of vision-related quality of life than thickness measures, with diffuse RGC+IPL loss as an indicator for diminished vision-related quality of life.

Baseline 24-2 Central Visual Field Damage Is Predictive of Global Progressive Field Loss.

The presence of central VF damage at baseline is significantly associated with more rapid global progression. Detection of central VF damage aids in stratification of high-risk patients who may need intensive surveillance and aggressive treatment.

Review of Hygiene and Disinfection Recommendations for Outpatient Glaucoma Care: A COVID Era Update.

This review focuses on best practices and recommendations for hygiene and disinfection to limit exposure and transmission of infection in outpatient glaucoma clinics during the current COVID-19 pandemic.

β-Zone Parapapillary Atrophy and Rates of Glaucomatous Visual Field Progression: African Descent and Glaucoma Evaluation Study.

Race had a significant effect on the association between baseline βPPA and rates of visual field progression in eyes with GON.

Manhattan Vision Screening and Follow-up Study in Vulnerable Populations (NYC-SIGHT): Design and Methodology.

This study targets vulnerable populations where they live to ensure improved access to and utilization of eye care services in those who are least likely to seek eye care.

Macular Damage in Glaucoma is Associated With Deficits in Facial Recognition.

Even with good central visual acuity, patients with glaucomatous macular damage exhibit diminished facial recognition, which is partly mediated through diminished CS.

The African Descent and Glaucoma Evaluation Study (ADAGES) III: Contribution of Genotype to Glaucoma Phenotype in African Americans: Study Design and Baseline Data.

With its large sample size, extensive specimen collection, and deep phenotyping of AD and ED glaucoma patients and control participants from different regions in the United States, the ADAGES III genomics study will address gaps in…

Rationale and Development of an OCT-Based Method for Detection of Glaucomatous Optic Neuropathy.

A decision tree was devised for testing and implementation in clinical practice and research that can be used by reading centers, researchers, and clinicians.

Glaucomatous Visual Field Progression in the African Descent and Glaucoma Evaluation Study (ADAGES): Eleven Years of Follow-up.

Rates of VF progression were similar despite higher treated IOP in the Black race group.

Patient Concerns Regarding Suspended Ophthalmic Care Due to COVID-19.

We found a majority of our patients were concerned about limitations in access to ophthalmic care and were fearful of disease progression.

Detection of Progression With 10-2 Standard Automated Perimetry: Development and Validation of an Event-Based Algorithm.

A new event-based progression algorithm using the 10-2 VF can identify eyes experiencing more rapid MD progression and may be used as a tool to assess progressive macular functional changes in glaucoma.

Disc Hemorrhages Are Associated With the Presence and Progression of Glaucomatous Central Visual Field Defects.

DH was associated with the presence and progression of central VF defects. DH identification should prompt intensive central VF monitoring and surveillance with 10-2 fields to detect progression.

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): Baseline Results and Costs of a Cluster-Randomized Trial.

This innovative study in public housing developments targeted high-risk populations, provided access to eye-care, and improved early detection of ocular diseases in New York City.

Reoperations for Complications Within 90 Days After Glaucoma Surgery.

Early postoperative complications requiring reoperations within the first 90 days after glaucoma surgery were low and comparable with previous studies. Common indications for reoperation within 90 days include wound leak and tube shunt-related issues.

Frequency of Optical Coherence Tomography Testing to Detect Progression in Glaucoma.

With high specificity and less variability than perimetry, a 6-month testing interval provides a reasonable trade-off for following glaucoma patients using OCT.

A Model of Progression to Help Identify Macular Damage Due to Glaucoma.

Second, the patterns of progression predicted by the model suggest alternative end points for clinical trials. Finally, the model provides a heuristic for future research concerning the anatomic basis of glaucomatous damage.

The Relationship Between Intraocular Pressure and Rates of Central Versus Peripheral Visual Field Progression.

The effect of IOP parameters on VF progression was statistically similar between central and peripheral VF regions.

A Comparison of Retrobulbar Versus Topical Anesthesia in Trabeculectomy and Aqueous Shunt Surgery.

Although supplemental anesthesia and pain scores were statistically increased in the topical group, the prevalence and the severity of pain was low.

American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection.

Glaucoma and the Human Microbiome.

Bacterial lipopolysaccharides (LPS) activate toll-like receptors (TLR) and mediate the human immune response.

Drug-Induced Liver Injury During a Glaucoma Neuroprotection Clinical Trial.

This report is important to share with the medical community, as other participants in glaucoma nicotinamide trials globally may have similar adverse events and many patients are using nicotinamide as a health supplement without medical supervision.

Automated Identification of Clinically Relevant Regions in Glaucoma OCT Reports Using Expert Eye Tracking Data and Deep Learning.

Our approach has the potential to assist ophthalmologists in diagnosing glaucoma by predicting the most medically salient regions on OCT reports.

The ICD-10 Glaucoma Severity Score Underestimates the Extent of Glaucomatous Optic Nerve Damage.

The ICD-10 system relies solely on damage seen on the 24-2 and as provides a 24-2 functional score rather than a "glaucoma" severity score.

Patient Navigators Improve In-Office Eye Exam Adherence After Community Eye Screenings in a Randomized Clinical Trial: NYC-SIGHT Study.

Patient navigators improved adherence to in-office eye exams following community-based eye health screenings and referral to ophthalmology among an underserved population.

Risk of Falls, Fear of Falling, and Rates of Visual Field Progression in Glaucoma in the African Descent and Glaucoma Evaluation Study.

A faster rate of MD progression is associated with a greater fear of falling and history of falls among AD and ED treated glaucoma patients.

Glaucoma Screening in the Primary Care Setting: Practical and Innovative Approaches.

Glaucoma Detection Using Optical Coherence Tomography: Reviewing the Pitfalls of Comparison to Normative Data.

This review describes various artifacts that originate from using a normative database to compare the individual's scans.

Detecting Established Glaucoma Using OCT Alone: Utilizing an OCT Reading Center in a Real-World Clinical Setting.

An OCT-based reading center is able to identify eyes with established glaucoma using OCT alone with high sensitivity and specificity.

Identifying Rapid Glaucoma Progression Using Hemifield Rates of Progression.

Hemifield ROPs are more sensitive to focal progression (or faster progression) than global rates and can aid in tailoring management and treatment decisions.

What is the Optimal Frequency of Visual Field Testing to Detect Rapid Progression Among Hypertensive Eyes?

Given the importance of not missing the conversion to glaucoma, the frequency of testing used in OHTS (6 mo) was optimal for the detection of progression in high-risk patients.

Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study.

The OHTS calculator can be applied to treated patients with OHTN, and repeat risk calculation after initiating IOP reduction may provide useful information that can aid in disease management.

Costs Associated With the Use of Disposable Gonioscopy Lenses and Tonometry Tips.

A widespread transition from reusable to disposable tonometry and gonioscopy equipment was associated with an additional cost of $965,161 over a 10-year period at a single institution.

Glaucoma Screening and Referral Risk Factors in a High-Risk Population: Follow-Up Study of the Manhattan Vision Screening Study.

Our findings support public health approaches that focus on community-based eye health screenings in high-risk populations and prioritize underserved communities.

The Role of Intraocular Pressure and Systemic Hypertension in the Progression of Glaucomatous Damage to the Macula.

Macular structural and functional parameters are more sensitive to IOP in terms of glaucomatous progression when compared with more conventional parameters.

Characterization of Temporal Delay and Modeling of Intraocular Pressure and Visual Field Progression in the African Descent and Glaucoma Evaluation Study (ADAGES).

ROP changes trail IOP changes by 4-7 months, an important consideration when obtaining additional VFs to capture or rule-out progression.

Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology.

This novel trial design may deliver valuable data on the neuroprotective potential of nicotinamide and pyruvate supplementation in glaucoma and improve our understanding of optimal study design for longitudinal randomized clinical trials focused on glaucoma neuroprotection.

Perimetry Testing in the 10th Decade of Life.

A total of 3951 VF tests were collected from 289 patients (530 eyes) who met the inclusion criteria.

A Morphologic Model of Glaucomatous Damage to the Macular Ganglion Cell Layer in Myopic Eyes.

The proposed model of glaucomatous damage patterns in macula GCL is applicable to myopic eyes, even with coexisting macular pathology. In cases deviating from the model, clinicians are advised to seek causes besides glaucoma.

Implementation and Consensus.

The provided abstract contains no information. Therefore, a précis summarizing key findings and clinical relevance cannot be generated.

Targeted Screening for Glaucoma.

Association of Psychosocial Factors with Activation Among Patients with Glaucoma.

We identified modifiable behavioral factors that could increase patients' self-perceived ability and confidence to manage their own eye care.

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): a nested cross-sectional assessment of falls risk within a cluster randomised trial.

This study detected a significant amount of falls risk in an underserved population.

Visual field progression patterns in the ocular hypertension treatment study correspond to vulnerability regions of the disc.

Development of VF loss in ocular hypertensive eyes appears to be consistent with the vulnerability zones previously described in glaucomatous eyes with established VF loss.

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT): optometric exam improves access and utilization of eye care services.

This community-based screening initiative demonstrated the effectiveness of optometric exams in detecting vision-affecting conditions and identified factors associated with having a recent dilated eye exam.

Improving glaucoma staging in clinical practice by combining the ICD-10 glaucoma severity classification system and optical coherence tomography.

Combining OCT and VF data provides better staging of glaucoma severity than VF data alone.

Self-reported Function, Health Resource Use, and Total Health Care Costs Among Medicare Beneficiaries With Glaucoma.

Glaucoma is associated with greater use of inpatient and home health aide services and with higher annual total and nonoutpatient medical costs.

Ophthalmic and Glaucoma Treatment Characteristics Associated With Changes in Health-related Quality of Life Before and After Newly Diagnosed Primary Open-angle Glaucoma in Nurses' Health Study Participants.

Among patients with incident glaucoma, no major factors were associated with change in physical well being.

Discrimination of Glaucoma Patients From Healthy Individuals Using Combined Parameters From Spectral-domain Optical Coherence Tomography in an African American Population.

These findings confirm that several individual RNFL, ONH, and GCA parameters have excellent diagnostic performance in differentiating glaucomatous patients from healthy patients in African American population.

Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D.

After the implementation of Part D, there was a decrease in the rate that beneficiaries with glaucoma reported engaging in cost-saving measures.

Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.

Assuming a willingness to pay of $50 000 per QALY, trabeculectomy and tube insertion are cost-effective compared with medical treatment alone.

Why Do People (Still) Go Blind from Glaucoma?